Variant
FLT3 I836
CI-VAR-00002027Explore in graph →CIViC 3232
Curated evidence
Evidence by cancer (5 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 31665578
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Acute Myeloid Leukemia4 | ||||||||
| FLT3 D835 OR FLT3 I836 | Gilteritinib | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID12622In a phase 3 trial comparing gilteritinib (120 mg/day) to salvage chemotherapy (SC) in adults with relapsed or refractory FLT3- mutated AML, patients were required to have FLT3 ITD or TKD (tyrosine ki… (full text at CIViC) PMID 31665578 · Perl et al., 2019 · Open in CIViC | civic |
| FLT3 ITD AND FLT3 D835 AND FLT3 I836 | Gilteritinib | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11260In this phase III, randomized trial, 371 patients with Relapsed or Refractory FLT3-Mutated AML were randomized 2:1 to receive either gilteritinib (at a dose of 120 mg per day) or salvage chemotherapy.… (full text at CIViC) PMID 31665578 · Perl et al., 2019 · Open in CIViC | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available